{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:10:58Z","timestamp":1790813458825,"version":"4.1.0"},"reference-count":89,"publisher":"American Society for Clinical Investigation","issue":"10","license":[{"start":{"date-parts":[[2024,5,22]],"date-time":"2024-05-22T00:00:00Z","timestamp":1716336000000},"content-version":"vor","delay-in-days":15,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,5,22]]},"abstract":"<jats:p>The homeostasis of IgG is maintained by the neonatal Fc receptor, FcRn. Consequently, antagonism of FcRn to reduce endogenous IgG levels is an emerging strategy for treating antibody-mediated autoimmune disorders using either FcRn-specific antibodies or an engineered Fc fragment. For certain FcRn-specific antibodies, this approach has resulted in reductions in the levels of serum albumin, the other major ligand transported by FcRn. Cellular and molecular analyses of a panel of FcRn antagonists have been carried out to elucidate the mechanisms leading to their differential effects on albumin homeostasis. These analyses have identified 2 processes underlying decreases in albumin levels during FcRn blockade: increased degradation of FcRn and competition between antagonist and albumin for FcRn binding. These findings have potential implications for the design of drugs to modulate FcRn function.<\/jats:p>","DOI":"10.1172\/jci.insight.176166","type":"journal-article","created":{"date-parts":[[2024,5,7]],"date-time":"2024-05-07T12:00:46Z","timestamp":1715083246000},"source":"Crossref","is-referenced-by-count":28,"title":["Differential effects of FcRn antagonists on the subcellular trafficking of FcRn and albumin"],"prefix":"10.1172","volume":"9","author":[{"given":"Guanglong","family":"Ma","sequence":"first","affiliation":[{"name":"Centre for Cancer Immunology, Faculty of Medicine, University of Southampton, Southampton, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew R.","family":"Crowley","sequence":"additional","affiliation":[{"name":"Centre for Cancer Immunology, Faculty of Medicine, University of Southampton, Southampton, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liesbeth","family":"Heyndrickx","sequence":"additional","affiliation":[{"name":"argenx, Zwijnaarde, Ghent, Belgium."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilse","family":"Rogiers","sequence":"additional","affiliation":[{"name":"argenx, Zwijnaarde, Ghent, Belgium."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eef","family":"Parthoens","sequence":"additional","affiliation":[{"name":"VIB BioImaging Core, Center for Inflammation Research, Ghent, Belgium."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jolien","family":"Van Santbergen","sequence":"additional","affiliation":[{"name":"argenx, Zwijnaarde, Ghent, Belgium."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raimund J.","family":"Ober","sequence":"additional","affiliation":[{"name":"Centre for Cancer Immunology, Faculty of Medicine, University of Southampton, Southampton, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladimir","family":"Bobkov","sequence":"additional","affiliation":[{"name":"argenx, Zwijnaarde, Ghent, Belgium."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans","family":"de Haard","sequence":"additional","affiliation":[{"name":"argenx, Zwijnaarde, Ghent, Belgium."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Ulrichts","sequence":"additional","affiliation":[{"name":"argenx, Zwijnaarde, Ghent, Belgium."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik","family":"Hofman","sequence":"additional","affiliation":[{"name":"argenx, Zwijnaarde, Ghent, Belgium."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Els","family":"Louagie","sequence":"additional","affiliation":[{"name":"argenx, Zwijnaarde, Ghent, Belgium."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bianca","family":"Balbino","sequence":"additional","affiliation":[{"name":"argenx, Zwijnaarde, Ghent, Belgium."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. Sally","family":"Ward","sequence":"additional","affiliation":[{"name":"Centre for Cancer Immunology, Faculty of Medicine, University of Southampton, Southampton, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"232","published-online":{"date-parts":[[2024,5,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/337184a0"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1002\/eji.1830150718"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1002\/eji.1830241025"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1021\/bi00045a005"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20021829"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1021\/bi052628y"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1002\/eji.200636556"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M113.537563"},{"key":"B9","article-title":"Unraveling the interaction between FcRn and albumin: opportunities for design of albumin-based therapeutics","volume":"5","author":"Sand","year":"2014","journal-title":"Front Immunol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms1607"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1093\/intimm\/dxg018"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.172.4.2021"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M117.794248"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-03061-x"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0402970101"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M202367200"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1091\/mbc.e03-11-0832"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0854.2006.00457.x"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abb0580"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1111\/aji.12972"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1002\/eji.1830260718"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1093\/intimm\/13.8.993"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1093\/intimm\/10.9.1289"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1172\/JCI6968"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.166.5.3266"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.179.7.4580"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0801717105"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0810796106"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2019.1602459"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.tips.2018.07.007"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M604292200"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0804182"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1038\/nbt0797-637"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.178.8.5390"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa062930"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1002\/art.27435"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-022-00821-1"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aan1208"},{"issue":"176","key":"B39","article-title":"Fully human monoclonal antibody inhibitors of the neonatal fc receptor reduce circulating IgG in non-human primates","volume":"6","author":"Nixon","year":"2015","journal-title":"Front Immunol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1276"},{"key":"B41","unstructured":"Antibody binding to FcRn for treating autoimmune diseases. https:\/\/patents.google.com\/patent\/US10336825B2\/en Updated July 2, 2019. Accessed April 19, 2024"},{"key":"B42","unstructured":"FcRn antibodies and methods of use thereof. https:\/\/patents.google.com\/patent\/WO2016123521A2\/en Updated August 4, 2016. Accessed April 19, 2024"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1038\/nbt1143"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000007600"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(21)00159-9"},{"key":"B46","unstructured":"UCB\u2019s Global Corporate Website. UCB announces U.S. FDA approval of RYSTIGGO (rozanolixizumab-noli) for the treatment of adults with generalized myasthenia gravis. https:\/\/www.ucb.com\/stories-media\/Press-Releases\/article\/UCB-announces-US-FDA-approval-of-RYSTIGGOR-rozanolixizumab-noli-for-the-treatment-of-adults-with-generalized-myasthenia-gravis Updated January 3, 2024. Accessed April 19, 2024"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(23)00077-7"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2024.1302714"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1007\/s40120-022-00345-9"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.20782"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9258(19)44690-5"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9258(19)41721-3"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchromb.2006.08.006"},{"key":"B54"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.892534"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbagen.2013.05.005"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(01)00957-3"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1186\/1742-4682-10-20"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics13081208"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1007\/s11239-020-02092-w"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1194\/jlr.M031336"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2016.02.026"},{"key":"B63","article-title":"Updates on the understanding and management of thyroid eye disease","volume":"13","author":"Men","year":"2021","journal-title":"Ther Adv Ophthalmol"},{"key":"B64","unstructured":"Immunovant. Immunovant Provides Corporate Updates and Reports Financial Results for the Quarter and Fiscal Year Ended March 31, 2021. https:\/\/d1io3yog0oux5.cloudfront.net\/_87424928cf7eed16019a4dd7bce4c468\/immunovant\/news\/2021-06-01_Immunovant_Provides_Corporate_Updates_and_Reports__2.pdf Updated June 1, 2021. Accessed April 19, 2024"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgad381"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbagen.2013.04.019"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2015.1008345"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-33764-1"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1172\/JCI97911"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1016\/0022-2836(92)91010-M"},{"issue":"5\u20136","key":"B71","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1159\/000163806","article-title":"Use of a human microvascular endothelial cell line as a model system to evaluate cholesterol uptake","volume":"61","author":"Pruckler","year":"2008","journal-title":"Pathobiology"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.4161\/mabs.4.2.19397"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1618291114"},{"key":"B74","unstructured":"Immunovant. Targeted Science, Tailored Solutions. Corporate Presentation May 2023. https:\/\/d1io3yog0oux5.cloudfront.net\/_0a6b5881bbeec80c678a0008b9f132d9\/immunovant\/db\/934\/9196\/pdf\/IMVT_Master+Deck_May+2023+v2.pdf Updated June 6, 2023. Accessed April 19, 2024"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-3495(97)78307-3"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijbiomac.2020.08.224"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1038\/s42003-021-01790-2"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01540"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1091\/mbc.e13-04-0174"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0700337104"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1242\/jcs.216499"},{"issue":"5","key":"B82","doi-asserted-by":"crossref","DOI":"10.1242\/jcs.226977","article-title":"Rab10 regulates tubular endosome formation through KIF13A and KIF13B motors","volume":"132","author":"Etoh","year":"2019","journal-title":"J Cell Sci"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1002\/bies.202200158"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1054425"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1083\/jcb.201711002"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-genet-102808-114910"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1152\/ajprenal.00172.2021"},{"key":"B88","unstructured":"FcRn antagonists and methods of use. https:\/\/patents.google.com\/patent\/WO2015100299A1\/en#patentCitations Updated July 2, 2015. Accessed April 19, 2024"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1016\/0161-5890(96)00004-1"}],"container-title":["JCI Insight"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/insight.jci.org\/articles\/view\/176166\/files\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T20:44:31Z","timestamp":1779137071000},"score":1,"resource":{"primary":{"URL":"https:\/\/insight.jci.org\/articles\/view\/176166"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,7]]},"references-count":89,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2024,4,23]]},"published-print":{"date-parts":[[2024,5,22]]}},"alternative-id":["10.1172\/jci.insight.176166"],"URL":"https:\/\/doi.org\/10.1172\/jci.insight.176166","relation":{},"ISSN":["2379-3708"],"issn-type":[{"value":"2379-3708","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,7]]},"article-number":"e176166"}}